Impact News +++ Lululemon, Broadcom And 3 Stocks To Watch Heading Into Friday (Benzinga) +++ BROADCOM Aktie -3,88%

REZOLUTE Aktie

>REZOLUTE Aktienkurs

1.15 EUR -3.4% (Tradegate)

Ask: 1.18 EUR / 5000 Stück

Bid: 1.14 EUR / 5000 Stück

Tagesumsatz: 8099 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REZOLUTE Aktie über LYNX handeln

Intraday

1 Jahr

>REZOLUTE Performance

1 Woche: -85,4%

1 Monat: -86,2%

3 Monate: -82,5%

6 Monate: -68,6%

1 Jahr: 0%

laufendes Jahr: 0%

>REZOLUTE Aktie

Name:

REZOLUTE INC. NEW DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US76200L3096 / A2QEWP

Symbol/ Ticker:

6HV1 (Frankfurt) / RZLT (NASDAQ)

Kürzel:

FRA:6HV1, ETR:6HV1, 6HV1:GR, NASDAQ:RZLT

Index:

Webseite:

https://rezolutebio.com/

Profil:

Rezolute, Inc. is a clinical-stage biopharmaceutic..
>Volltext..

Marktkapitalisierung:

780.55 Mio. EUR

Unternehmenswert:

652.91 Mio. EUR

Umsatz:

EBITDA:

-70.71 Mio. EUR

Nettogewinn:

-65.96 Mio. EUR

Gewinn je Aktie:

-0.79 EUR

Schulden:

1.24 Mio. EUR

Liquide Mittel:

7.78 Mio. EUR

Operativer Cashflow:

-60.24 Mio. EUR

Bargeldquote:

14.91

Umsatzwachstum:

Gewinnwachstum:

-5.66%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

REZOLUTE

Letzte Datenerhebung:

12.12.25

>REZOLUTE Kennzahlen

Aktien/ Unternehmen:

Aktien: 92.73 Mio. St.

Frei handelbar: 79.92%

Leerverk. Aktien: 11.31%

Rückkaufquote: -11.25%

Mitarbeiter: 71

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 46.13%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 6.97

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -54.73%

Eigenkaprendite: -59.23%

>REZOLUTE Peer Group

Es sind 599 Aktien bekannt.

>REZOLUTE Chart & Kurs - NASDAQ

>REZOLUTE News

11.12.25 - 14:27	Rezolute plunges as lead asset fails in late-stage trial (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.12.25 - 14:01	Rezolute-Aktie bricht nach Fehlschlag in Phase-3-Studie um 90 % ein (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

01.12.25 - 17:30	How Much Upside is Left in Rezolute (RZLT)? Wall Street Analysts Think 56.58% (Zacks)
	The consensus price target hints at a 56.6% upside potential for Rezolute (RZLT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....

12.11.25 - 19:45	All You Need to Know About Rezolute (RZLT) Rating Upgrade to Buy (Zacks)
	Rezolute (RZLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

12.11.25 - 17:30	Can Rezolute (RZLT) Climb 49.4% to Reach the Level Wall Street Analysts Expect? (Zacks)
	The consensus price target hints at a 49.4% upside potential for Rezolute (RZLT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....

10.11.25 - 23:33

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that it has granted as of October 31, 2025 equity inducement awards to two new employees. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Rezolute....

07.11.25 - 00:06	Rezolute GAAP EPS of -$0.18 beats by $0.08 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 13:33	Rezolute to Host Virtual Investor Event on Ersodetug Development Program (GlobeNewswire EN)
	Webcast scheduled for Monday, November 10 at 12:00 pm EST Webcast scheduled for Monday, November 10 at 12:00 pm EST...

09.10.25 - 22:09

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

REDWOOD CITY, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that it has granted as of September 30, 2025 equity inducement awards to two new employees. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Rezolute....

18.09.25 - 10:51	Rezolute GAAP EPS of -$0.26 misses by $0.01 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.09.25 - 22:09	Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
	REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2025....

27.08.25 - 13:33	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:...

20.08.25 - 13:33	Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer (GlobeNewswire EN)
	Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug...

22.07.25 - 13:33	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire EN)
	REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 29-30, 2025....

17.07.25 - 23:15	Rezolute files to sell 1.3M shares of common stock for holders (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.07.25 - 13:33

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) (GlobeNewswire EN)

REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that the abstract titled “Preliminary Patient Demographics And Baseline Characteristics From A Phase 3 Study (sunRIZE) Of Ersodetug For Hypoglycemia Due To Congenital Hyperinsulinism: Trial In Progress” has been selected for a late-breaking presentation at ENDO 2025 taking place July 12-15, 2025 in San Francisco, CA, USA....

26.06.25 - 17:01	Insiderhandel: Chief Medical Officer kauft Aktien von Rezolute im Wert von 10939 USD (Insiderkauf)
	Roberts, Brian Kenneth - Vorstand - Tag der Transaktion: 2025-06-25...

24.06.25 - 21:01	Insiderhandel: CFO kauft Aktien von Rezolute im Wert von 20250 USD (Insiderkauf)
	Evans, Daron - Vorstand - Tag der Transaktion: 2025-06-24...

24.06.25 - 21:00	Rezolute ticks higher following disclosure of CFO stock buy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.06.25 - 19:01	Insiderhandel: Aufsichtsrat kauft Aktien von Rezolute im Wert von 3999999 USD (Insiderkauf)
	Kim, Young-Jin - Aufsichtsrat - Tag der Transaktion: 2025-06-13...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Kaufe und verkaufe ehrlich, dann wirst du nie einen Verlust haben. - Weisheiten - Wissen - Wahrheiten aus dem Orient

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram